OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy

British Journal of Cancer

Volumn 112, Issue 5, 2015, Pages 857-865

  Teft, W A ^a   Welch, S ^b   Lenehan, J ^b   Parfitt, J ^a   Choi, Y H ^b   Winquist, E ^b   Kim, R B ^a,b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG INTOXICATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; VOMITING; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84928702607     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.5     Document Type: Article

References (35)

1. R Core Team (2013) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria.
2. Akiyama Y, Fujita K, Ishida H, Sunakawa Y, Yamashita K, Kawara K, Miwa K, Saji S, Sasaki Y (2012) Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet 27: 325-335.
3. Bekaii-Saab T, Wu C (2014) Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol 91(1): 9-34.
4. Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L (2013) Analysis of UGT1A1∗28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. J Cancer Res Clin Oncol 139: 1579-1589.
5. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13: 3269-3275.
6. De Mattia E, Toffoli G, Polesel J, D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E (2013) Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics 23: 549-557.
7. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P (2011) Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther 12: 780-787.
8. Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y (2014) Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 31: 204-215.
9. Fujiwara Y, Minami H (2010) An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 11: 391-406.
10. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Bystrom P, Sorbye H, Wadelius M (2011) Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11: 61-71.
11. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS (2008) Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59: 69-75.
12. Han S, Kim K, Thakkar N, Kim D, Lee W (2013) Role of hypoxia inducible factor-1alpha in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochem Pharmacol 86: 816-823.
13. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL (2007) UGT1A1∗28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99: 1290-1295.
14. Hu ZY, Yu Q, Pei Q, Guo C (2010) Dose-dependent association between UGT1A1∗28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16: 3832-3842.
15. Imai S, Kikuchi R, Tsuruya Y, Naoi S, Nishida S, Kusuhara H, Sugiyama Y (2013) Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines. Pharm Res 30: 2880-2890.
16. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27: 2604-2614.
17. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47.
18. Kweekel D, Guchelaar HJ, Gelderblom H (2008) Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 34: 656-669.
19. Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, El-Rifai W (2008) Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 68: 10315-10323.
20. Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1∗28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS One 8: e58489.
21. Marsh S, Hoskins JM (2010) Irinotecan pharmacogenomics. Pharmacogenomics 11: 1003-1010.
22. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96: 1585-1592.
23. Mathijssen RH, Gurney H (2009) Irinogenetics: how many stars are there in the sky? J Clin Oncol 27: 2578-2579.
24. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9: 3246-3253.
25. Nagai M, Furihata T, Matsumoto S, Ishii S, Motohashi S, Yoshino I, Ugajin M, Miyajima A, Chiba K (2012) Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun 418: 818-823.
26. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E (2013) Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 5: 1.
27. Obaidat A, Roth M, Hagenbuch B (2012) The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52: 135-151.
28. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L (2013) Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127: 1404-1412.
29. Paulik A, Grim J, Filip S (2012) Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta Medica (Hradec Kralove) 55: 153-159.
30. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J (2003) Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13: 741-757.
31. Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H (2010) Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66: 95-105.
32. Sakaguchi S, Garcia-Bournissen F, Kim R, Schwarz UI, Nathan PC, Ito S (2009) Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child 94: 981-982.
33. Takane H, Kawamoto K, Sasaki T, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I (2009) Life-threatening toxicities in a patient with UGT1A1∗6/∗28 and SLCO1B1∗15/∗15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 63: 1165-1169.
34. Thakkar N, Kim K, Jang ER, Han S, Kim D, Merchant N, Lockhart AC, Lee W (2013) A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm 10: 406-416.
35. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, Mano N (2008) Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 260: 163-169.